These results documents that while patients with MYCN amplification have characteristic signaling activities that trigger processes which contribute to bad prognostic, such as the inhibition of the JNK pathway or potentially defective DNA repair, much of the cancer hallmarks are not exclusive of this group. The gene discussed is MYCN; the disease is cancer.